Y-Mabs Therapeutics (YMAB) has issued an update.
Y-mAbs Therapeutics, following the resignation of Executive VP and CFO Bo Kruse, has finalized a separation agreement facilitating his departure by July 31, 2024, with benefits including continued salary, a pro-rated bonus, and equity vesting. Concurrently, the company has entered a consultancy agreement with Kruse’s firm for one year, starting August 1, 2024, where he will provide financial and governance advice for a fixed monthly fee, ensuring his expertise remains accessible to Y-mAbs during the transition.
See more data about YMAB stock on TipRanks’ Stock Analysis page.
